Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
The British Journal of Diabetes & Vascular Disease
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Shepherd, J.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Raising HDL-C and lowering triglycerides: benefits beyond LDL-C modification

James Shepherd

Department of Vascular Biochemistry, Division of Cardiovascular and Medical Sciences, Macewen Building, Glasgow Royal Infirmary, North Glasgow University Hospital Division, 8 Alexandra Parade, Glasgow, G31 2ER, UK, sbrownlie{at}clinmed.gla.ac.uk

Reduction of low-density lipoprotein cholesterol (LDL-C) is central to the management of cardiovascular risk associated with dyslipidaemia. Yet, at best, this strategy is only capable of a reduction of about 50% in ischaemic vascular disease. Therefore, there is still a need for interventive strategies to improve the situation. Triglyceride lowering and high-density lipoprotein cholesterol (HDL-C) elevation feature prominently in this context, a viewpoint increasingly adopted by international treatment guidelines. This article reviews current thinking on the subject and offers additional treatment strategies for the dyslipidaemic patient.

Key Words: low and high-density lipoproteins • apolipoprotein B • apolipoprotein AI • fibrates • statins • nicotinic acid.

The British Journal of Diabetes & Vascular Disease, Vol. 5, No. 1 suppl, S12-S16 (2005)
DOI: 10.1177/14746514050050010401
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?